20 November 2018 - Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.

The announcement comes just one month after the US Food and Drug Administration also green-lighted the drug in this setting.

Read Pharma Times article